Free

MedTech Market Access & HEOR Workshop

Event Information

Share this event

Date and Time

Location

Location

Online Event

Event description
Opening the door to more efficient market access and improved patient care through health economics and outcomes research (HEOR).

About this Event

Together, ISPOR, Alira Health, and MassMEDIC developed an educational event that will focus on HEOR approaches and address evolving market demands and challenges.

Scheduled for October 29, this event will help the MedTech industry better engage with and support all stakeholders, including providers, payers, regulators, and patient representatives, throughout their lifecycle from development and into commercialization and use.

Program Information:

Session 1 | HEOR in the U.S., and differences with the EU

In this session, we'll define HEOR within the context of the US and establish the key differences with the EU.

For Discussion:

  • What is HEOR in the context of the US healthcare system?
  • How have HEOR methods helped medical devices establish their value proposition in the US?
  • What are the differences between the US and the EU?

Presenters:

  • Martin Gold, VP, Global Health Economics & Riembursement at Edwards Lifesciences
  • Russ Montgomery, Director, Health Economics and Market Access at Ambu
  • Scott Tackett, VP, Global Access, Value & Economics at Intuitive

Session 2 | Commercial Challenges for Medical Devices in the US

This session will highlight, in broad strokes, the significant commercial challenges that medical devices face in the US. The scope of challenges are enormous and could differ depending on the type of medical devices and indications.

For Discussion:

  • What are your personal experiences with different indications and types of products you have worked?
  • What are key challenges or opportunities you have faced and you foresee in the evolving era of the pandemic?
  • How HEOR plays a critical role in addressing these challenges or opportunities?

Presenters:

  • Arthi Chandran, Vice President and Head of WW Health Economics and Outcomes Research at BD
  • Michael Jaff, Chief Medical Officer & Vice President, Peripheral Interventions at Boston Scientific
  • Julie Lankiewicz, Global Head, Clinical Affairs and HEOR, Bose Health Division

Session 3 | Changing Payment Situations and need for HEOR

This session will highlight how payment systems are evolving in the US and moving towards value-based engagement. More importantly, how medical devices can enable a value-based contract and the risks and benefits of being engaged in such a contract.

For Discussion:

  • What are your personal experiences with the changing reimbursement landscape?
  • How have value-based healthcare evolved and affected the medical devices industry?
  • How HEOR plays a critical role in achieving a value-based engagement?

Presenters:

  • Ed Hedblom, Senior Director, Market Access & Value Based Solutions, 3M Medical Solutions Division at 3M
  • Louis Jacques, Chief Clinical Officer at ADVI Health, LLC

Session 4 | Communicating with payors and provider and the need for HEOR

This session will highlight, making participants understand VACs, communicating with VACs, and what value means for the committees. More importantly, how medical devices should take into consideration while discussing with VACs.

For Discussion:

  • Define VACs, its composition, structure, and role in the procurement process at hospitals.
  • How have VACs evolved and affected the medical devices industry?
  • What are the different opportunities available for medical devices companies to engage with VAC?

Presenters:

  • Gloria Graham , Industry Business Education Collaborative.
  • Barbara Strain , Principal Consultant at Barbara Strain Consulting LLC

Session 5 | Investor's decisions and the use of HEOR

In the current climate there are several major challenges or trends in investing in medical devices, putting future innovation at risk. There is huge uncertainty in the period between the initial investment and creation of a commercially-viable product. Increased reimbursement and commercialization risks for new products​ is considered a major barrier for investment decisions. Investors are more willing to invest in technologies that can demonstrate differentiated value, quickly gain coverage, be commercially successful, and generate a sufficient return.

Medical devices need to have a more sophisticated understanding of who their customers are, how they define value, and tailor value propositions accordingly.

Presenters:

  • Peter Stebbins, VP, Business Development at Johnson & Johnson
  • David Uffer, Senior Partner, Vice President of MedTech, Alira Health

Share with friends

Date and Time

Location

Online Event

Save This Event

Event Saved